Berman Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $47K | Buy |
494
+83
| +20% | +$7.9K | 0.01% | 702 |
|
|
2021
Q2 | $39K | Buy |
411
+239
| +139% | +$22.7K | 0.01% | 671 |
|
|
2021
Q1 | $16K | Buy |
172
+12
| +8% | +$1.12K | ﹤0.01% | 865 |
|
|
2020
Q4 | $15K | Sell |
160
-3
| -2% | -$281 | ﹤0.01% | 764 |
|
|
2020
Q3 | $15K | Sell |
163
-13
| -7% | -$1.2K | ﹤0.01% | 671 |
|
|
2020
Q2 | $20K | Buy |
176
+13
| +8% | +$1.48K | 0.01% | 540 |
|
|
2020
Q1 | $13K | Buy |
163
+22
| +16% | +$1.76K | ﹤0.01% | 606 |
|
|
2019
Q4 | $15K | Sell |
141
-15
| -10% | -$1.6K | ﹤0.01% | 616 |
|
|
2019
Q3 | $14K | Buy |
156
+15
| +11% | +$1.35K | ﹤0.01% | 621 |
|
|
2019
Q2 | $11K | Buy |
141
+65
| +86% | +$5.07K | ﹤0.01% | 696 |
|
|
2019
Q1 | $6K | Buy |
76
+71
| +1,420% | +$5.61K | ﹤0.01% | 824 |
|
|
2018
Q4 | $0 | Buy |
+5
| New | – | ﹤0.01% | 1219 |
|